cached image

Kim A. Neve, Ph.D. - Publications

Portland VA Medical Center, United States 
Dopamine receptors, signal transduction, cellular and molecular biology of G protein-coupled receptors, structure-function analysis of dopamine receptors, behavioral

59 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A. Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function. Plos One. 11: e0152581. PMID 27031617 DOI: 10.1371/Journal.Pone.0152581  0.36
2015 Gantz SC, Robinson BG, Buck DC, Bunzow JR, Neve RL, Williams JT, Neve KA. Distinct regulation of dopamine D2S and D2L autoreceptor signaling by calcium. Elife. 4. PMID 26308580 DOI: 10.7554/Elife.09358  0.36
2015 Vanderwerf SM, Buck DC, Wilmarth PA, Sears LM, David LL, Morton DB, Neve KA. Role for Rab10 in Methamphetamine-Induced Behavior. Plos One. 10: e0136167. PMID 26291453 DOI: 10.1371/Journal.Pone.0136167  0.36
2014 Clayton CC, Donthamsetti P, Lambert NA, Javitch JA, Neve KA. Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor. The Journal of Biological Chemistry. 289: 33663-75. PMID 25336643 DOI: 10.1074/Jbc.M114.605378  0.36
2014 Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Journal of Neurochemistry. 131: 418-31. PMID 25041389 DOI: 10.1111/Jnc.12825  0.36
2014 Abraham AD, Neve KA, Lattal KM. Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiology of Learning and Memory. 108: 65-77. PMID 24269353 DOI: 10.1016/J.Nlm.2013.11.007  0.36
2013 Neve KA, Ford CP, Buck DC, Grandy DK, Neve RL, Phillips TJ. Normalizing dopamine D2 receptor-mediated responses in D2 null mutant mice by virus-mediated receptor restoration: comparing D2L and D2S. Neuroscience. 248: 479-87. PMID 23811070 DOI: 10.1016/J.Neuroscience.2013.06.035  0.36
2011 Gantz SC, Ford CP, Neve KA, Williams JT. Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 12629-37. PMID 21880923 DOI: 10.1523/Jneurosci.0684-11.2011  0.36
2011 Neve K, Sibley DR. D2-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60156-4  0.36
2011 Neve K, Sibley DR. D3 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60154-0  0.36
2011 Sibley DR, Neve K. D1 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60153-9  0.36
2011 Sibley DR, Neve K. D1-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60152-7  0.36
2005 Neve RL, Neve KA, Nestler EJ, Carlezon WA. Use of herpes virus amplicon vectors to study brain disorders. Biotechniques. 39: 381-91. PMID 16206910 DOI: 10.2144/05393Ps01  0.36
2005 Watts VJ, Neve KA. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacology & Therapeutics. 106: 405-21. PMID 15922020 DOI: 10.1016/J.Pharmthera.2004.12.005  0.36
2004 Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. Journal of Receptor and Signal Transduction Research. 24: 165-205. PMID 15521361 DOI: 10.1081/Rrs-200029981  0.36
2003 Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferré S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. The Journal of Biological Chemistry. 278: 46741-9. PMID 12933819 DOI: 10.1074/Jbc.M306451200  0.36
2003 McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 6914-27. PMID 12890786 DOI: 10.1523/Jneurosci.23-17-06914.2003  0.64
2001 Janowsky A, Neve K, Eshleman AJ. Uptake and release of neurotransmitters. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit7.9. PMID 18428535 DOI: 10.1002/0471142301.Ns0709S02  0.36
2001 Watts VJ, Taussig R, Neve RL, Neve KA. Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of Galphas-insensitive mutants of adenylyl cyclase V. Molecular Pharmacology. 60: 1168-72. PMID 11723222 DOI: 10.1124/Mol.60.6.1168  0.36
2001 Nelson CS, Ikeda M, Gompf HS, Robinson ML, Fuchs NK, Yoshioka T, Neve KA, Allen CN. Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124. Molecular Endocrinology (Baltimore, Md.). 15: 1306-17. PMID 11463855 DOI: 10.1210/Mend.15.8.0681  0.36
2001 Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Molecular Pharmacology. 60: 373-81. PMID 11455025 DOI: 10.1124/Mol.60.2.373  0.36
2000 Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL. Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. Clinical and Experimental Pharmacology & Physiology. 27: 9-13. PMID 10696522 DOI: 10.1046/J.1440-1681.2000.03210.X  0.36
1999 Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. The Journal of Pharmacology and Experimental Therapeutics. 289: 877-85. PMID 10215666  0.36
1999 Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HH, Neve KA. Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors. Psychopharmacology. 141: 83-92. PMID 9952069 DOI: 10.1007/S002130050810  0.36
1998 Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8692-9. PMID 9786976  0.36
1998 Wilcox RE, Tseng T, Brusniak MY, Ginsburg B, Pearlman RS, Teeter M, DuRand C, Starr S, Neve KA. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. Journal of Medicinal Chemistry. 41: 4385-99. PMID 9784114 DOI: 10.1021/Jm9800292  0.36
1998 Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse (New York, N.Y.). 30: 97-106. PMID 9704886 DOI: 10.1002/(Sici)1098-2396(199809)30:1<97::Aid-Syn12>3.0.Co;2-M  0.36
1998 Song S, Wang Y, Bak SY, During MJ, Bryan J, Ashe O, Ullrey DB, Trask LE, Grant FD, O'Malley KL, Riedel H, Goldstein DS, Neve KA, LaHoste GJ, Marshall JF, et al. Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 4119-32. PMID 9592092 DOI: 10.1523/Jneurosci.18-11-04119.1998  0.36
1997 Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA. Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. Journal of Neurochemistry. 69: 1459-66. PMID 9326274 DOI: 10.1046/J.1471-4159.1997.69041459.X  0.36
1997 Watts VJ, Neve KA. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Molecular Pharmacology. 52: 181-6. PMID 9271339 DOI: 10.1124/Mol.52.2.181  0.36
1996 Watts VJ, Neve KA. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Molecular Pharmacology. 50: 966-76. PMID 8863843  0.36
1995 Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, Neve KA. Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse (New York, N.Y.). 21: 1-9. PMID 8525456 DOI: 10.1002/Syn.890210102  0.36
1995 Eshleman AJ, Neve RL, Janowsky A, Neve KA. Characterization of a recombinant human dopamine transporter in multiple cell lines. The Journal of Pharmacology and Experimental Therapeutics. 274: 276-83. PMID 7616409  0.36
1995 Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology. 118: 401-9. PMID 7568626 DOI: 10.1007/Bf02245940  0.36
1995 Neve KA, Rosser MP, Barber DL. [12] Regulation of Na+-H+ exchange by G protein-coupled receptors Methods in Neurosciences. 25: 225-241. DOI: 10.1016/S1043-9471(05)80042-4  0.36
1994 Eshleman AJ, Henningsen RA, Neve KA, Janowsky A. Release of dopamine via the human transporter. Molecular Pharmacology. 45: 312-6. PMID 7906856  0.36
1993 Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. European Journal of Pharmacology. 239: 271-3. PMID 8223910 DOI: 10.1016/0014-2999(93)91012-C  0.36
1993 Neve RL, Ivins KJ, Neve KA, Bahr BA, Vanderklish PW, Arai A, Lynch G. The Use of Antisense Intervention to Decipher the Role of the Neuronal Growth-Associated Protein GAP-43 Neuroprotocols. 2: 39-49. DOI: 10.1006/Ncmn.1993.1007  0.36
1992 Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. The Journal of Pharmacology and Experimental Therapeutics. 261: 1282-90. PMID 1534844  0.36
1992 Neve KA, Kozlowski MR, Rosser MP. Dopamine D2 receptor stimulation of Na+/H+ exchange assessed by quantification of extracellular acidification. The Journal of Biological Chemistry. 267: 25748-53. PMID 1361188  0.36
1991 Joyce JN, Janowsky A, Neve KA. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. The Journal of Pharmacology and Experimental Therapeutics. 257: 1253-63. PMID 1828505  0.36
1991 Neve KA, Neve RL, Fidel S, Janowsky A, Higgins GA. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proceedings of the National Academy of Sciences of the United States of America. 88: 2802-6. PMID 1826366 DOI: 10.1073/Pnas.88.7.2802  0.36
1990 Neve KA, Henningsen RA, Kinzie JM, De Paulis T, Schmidt DE, Kessler RM, Janowsky A. Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand. The Journal of Pharmacology and Experimental Therapeutics. 252: 1108-16. PMID 2138666  0.36
1988 Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 336: 783-7. PMID 2974511 DOI: 10.1038/336783A0  0.36
1988 Luedtke RR, Korner M, Neve KA, Molinoff PB. Monoclonal antibodies with high affinity for spiroperidol. Journal of Neurochemistry. 50: 1253-62. PMID 2964511 DOI: 10.1111/J.1471-4159.1988.Tb10602.X  0.36
1988 Abramson SN, Martin MW, Hughes AR, Harden TK, Neve KA, Barrett DA, Molinoff PB. Interaction of beta-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc- S49 lymphoma cells. Biochemical Pharmacology. 37: 4289-97. PMID 2848525 DOI: 10.1016/0006-2952(88)90609-0  0.36
1986 Neve KA, Molinoff PB. Turnover of beta 1- and beta 2-adrenergic receptors after down-regulation or irreversible blockade. Molecular Pharmacology. 30: 104-11. PMID 3016496  0.36
1986 Neve KA, McGonigle P, Molinoff PB. Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors. The Journal of Pharmacology and Experimental Therapeutics. 238: 46-53. PMID 3014123  0.36
1986 McGonigle P, Neve KA, Molinoff PB. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Molecular Pharmacology. 30: 329-37. PMID 2876374  0.36
1986 Neve KA, Molinoff PB. Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. The American Journal of Cardiology. 57: 17F-22F. PMID 2871741 DOI: 10.1016/0002-9149(86)90883-0  0.36
1985 Neve KA, Loeschen S, Marshall JF. Denervation accelerates the reappearance of neostriatal D-2 receptors after irreversible receptor blockade. Brain Research. 329: 225-31. PMID 3156659 DOI: 10.1016/0006-8993(85)90528-1  1
1985 Neve KA, Barrett DA, Molinoff PB. Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists. The Journal of Pharmacology and Experimental Therapeutics. 235: 657-64. PMID 2867205  0.36
1984 Altar CA, Walter RJ, Neve KA, Marshall JF. Computer-assisted video analysis of [3H]spiroperidol binding autoradiographs. Journal of Neuroscience Methods. 10: 173-88. PMID 6738107 DOI: 10.1016/0165-0270(84)90054-2  1
1984 Neve KA, Altar CA, Wong CA, Marshall JF. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury. Brain Research. 302: 9-18. PMID 6428705 DOI: 10.1016/0006-8993(84)91280-0  1
1984 Neve KA, Marshall JF. The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive in the rat. Neuroscience Letters. 46: 77-83. PMID 6203067 DOI: 10.1016/0304-3940(84)90202-7  1
1983 Altar A, Neve KA, Loughlin SE, Marshall JF, Fallon JH. The crossed mesostriatal projection: neurochemistry and developmental response to lesion. Brain Research. 279: 1-8. PMID 6416611 DOI: 10.1016/0006-8993(83)90157-9  0.36
1983 Kozlowski MR, Neve KA, Grisham JE, Marshall JF. Chronic lithium administration alters behavioral recovery from nigrostriatal injury: effects on neostriatal [3H]spiroperidol binding sites. Brain Research. 267: 301-11. PMID 6409351 DOI: 10.1016/0006-8993(83)90882-X  1
1983 Marshall JF, Drew MC, Neve KA. Recovery of function after mesotelencephalic dopaminergic injury in senescence. Brain Research. 259: 249-60. PMID 6297672 DOI: 10.1016/0006-8993(83)91255-6  1
1982 Neve KA, Kozlowski MR, Marshall JF. Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Research. 244: 33-44. PMID 6288182 DOI: 10.1016/0006-8993(82)90901-5  1
Show low-probability matches.